Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023.
Joshi M, Tuanquin L, Zhu J, Walter V, Schell T, Kaag M, Kilari D, Liao J, Holder SL, Emamekhoo H, Sankin A, Merrill S, Zheng H, Warrick J, Hauke R, Gartrel B, Stein M, Drabick J, Degraff DJ, Zakharia Y. Joshi M, et al. Among authors: drabick j. J Immunother Cancer. 2023 Feb;11(2):e006551. doi: 10.1136/jitc-2022-006551. J Immunother Cancer. 2023. PMID: 36822667 Free PMC article. Clinical Trial.
Tumor Heterogeneity Shapes Survival Dynamics in Drug-Treated Cells, Revealing Size-Drifting Subpopulations.
Vangala V, Chen YC, Dinavahi SS, Gowda K, Lone NA, Herlyn M, Drabick J, Helm K, Zhu J, Neves RI, Sharma AK, Berg A, Archetti M, Amin S, Schell TD, Robertson GP. Vangala V, et al. Among authors: drabick j. ACS Pharmacol Transl Sci. 2024 Oct 17;7(11):3573-3584. doi: 10.1021/acsptsci.4c00453. eCollection 2024 Nov 8. ACS Pharmacol Transl Sci. 2024. PMID: 39539277
Editorial: Checkpoint inhibition in hematologic malignancies.
Pu JJ, Drabick JJ, Prockop SE. Pu JJ, et al. Among authors: drabick jj. Front Oncol. 2024 Jun 3;14:1429854. doi: 10.3389/fonc.2024.1429854. eCollection 2024. Front Oncol. 2024. PMID: 38887228 Free PMC article. No abstract available.
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
Zakharia Y, McWilliams RR, Rixe O, Drabick J, Shaheen MF, Grossmann KF, Kolhe R, Pacholczyk R, Sadek R, Tennant LL, Smith CM, Kennedy EP, Link CJ Jr, Vahanian NN, Yu J, Shen SS, Brincks EL, Rossi GR, Munn D, Milhem M. Zakharia Y, et al. Among authors: drabick j. J Immunother Cancer. 2021 Jun;9(6):e002057. doi: 10.1136/jitc-2020-002057. J Immunother Cancer. 2021. PMID: 34117113 Free PMC article. Clinical Trial.
127 results